OTCMMDXXF
Market cap15mUSD
Jan 10, Last price
0.19USD
1D
-3.14%
1Q
155.94%
IPO
-38.53%
Name
Pharmala Biotech Holdings Inc
Chart & Performance
P/E
—
P/S
42.67
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
532k
+581.44%
Net income
-780k
L-20.88%
CFO
-340k
L-45.69%
Profile
Pharmala Biotech Holdings Inc., doing business as PharmAla, focuses on the developing, manufacturing, and commercializing of substituted methylenedioxy-phenethylamines (MDXX) active pharmaceutical ingredients. It also provides MDXX class compounds, such as 1,3-Benzodioxolyl-Nmethylbutanamine (MBDB); and 3,4-Methylenedioxy-N-ethylamphetamine (MDEA/MDE), as well as formulations of MDXX compounds. The company is headquartered in Vancouver, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY |
|---|---|---|---|
| 2023‑08 | 2022‑08 | 2021‑08 | |
| Income | |||
Revenues | 532 581.44% | 78 | |
Cost of revenue | 1,063 | 1,052 | |
Unusual Expense (Income) | |||
NOPBT | (531) | (973) | |
NOPBT Margin | |||
Operating Taxes | (3) | ||
Tax Rate | |||
NOPAT | (531) | (973) | |
Net income | (780) -20.88% | (986) -60.72% | |
Dividends | |||
Dividend yield | |||
Proceeds from repurchase of equity | 189 | ||
BB yield | |||
| Debt | |||
Debt current | 254 | (372) | |
Long-term debt | |||
Deferred revenue | |||
Other long-term liabilities | |||
Net debt | 58 | (1,224) | |
| Cash flow | |||
Cash from operating activities | (340) | (625) | |
CAPEX | (995) | ||
Cash from investing activities | (507) | (995) | |
Cash from financing activities | 189 | ||
FCF | (468) | (975) | |
| Balance | |||
Cash | 195 | 852 | |
Long term investments | |||
Excess cash | 168 | 848 | |
Stockholders' equity | 1,007 | 1,527 | |
Invested Capital | 1,469 | 686 | |
ROIC | |||
ROCE | |||
| EV | |||
Common stock shares outstanding | 84,527 | 82,999 | |
Price | |||
Market cap | |||
EV | |||
EBITDA | (479) | (961) | |
EV/EBITDA | |||
Interest | |||
Interest/NOPBT | |||